Clinical trials: Stage I Lung Cancer
Non Small Cell Lung Cancer
Phase I Combination Ixabepilone + Cisplatin
The purpose of this study is to determine the highest dose of ixabepilone that can be given safely with cisplatin without causing severe or life-threatening side effects and for some patients with non-small cell lung cancer, the…
- Trial name
- NCT00832117
- Testing
- Ixabepilone, Cisplatin
- Where
- 7 sites in United States, Italy
- Volunteers
- 30 people
- Sponsor
- R-Pharm
Pancreatic Cancer, BRAF Mutant Colorectal Cancer
A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands
The primary purpose of this study was to find the recommended dose of LGK974 as a single agent and in combination with PDR001 that can be safely given to adult patients with selected solid malignancies that had progressed despite…
- Conditions
- Pancreatic Cancer, BRAF Mutant Colorectal Cancer, Melanoma, Triple Negative Breast Cancer
- Trial name
- NCT01351103
- Testing
- LGK974, PDR001
- Where
- 20 sites in United States, Canada and 5 more
- Volunteers
- 185 people
- Sponsor
- Novartis Pharmaceuticals
NSCLC
IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC
The purpose of this study is to determine if IO102 combined with pembrolizumab with or without chemotherapy is safe tolerable and effective in the treatment of Non-small Cell Lung Carcinoma (NSCLC).
- Trial name
- NCT03562871
- Testing
- IO102, pembrolizumab (Keytruda), Carboplatin (Carboplatin Kabi)
- Where
- 13 sites in Germany, Netherlands and 2 more
- Volunteers
- 109 people
- Sponsor
- IO Biotech
Asthma
Safety, Tolerability and Pharmacokinetics of Inhaled Laninamivir Octanoate TwinCaps® DPI in Adults With Chronic Asthma
This is a single centre, randomized, double-blind, placebo-controlled, single ascending dose study, in which the safety and pharmacokinetics of laninamivir octanoate administered by inhalation via the TwinCaps® DPI will be…
- Trial name
- NCT02022761
- Testing
- Laninamivir octanoate
- Where
- United Kingdom
- Volunteers
- 32 people
- Sponsor
- Biota Scientific Management Pty Ltd
Non-Small Cell Lung Cancer、EGFR Sensitive Mutation
Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation
To evaluate the safety and tolerance of MCLA-129 combined with Befotertinib in patients with advanced non-small cell lung cancer with EGFR-sensitive mutations.
- Trial name
- NCT06015568
- Testing
- MCLA-129: 1500mg or 2000mg IV Q2W, Befotertinib: 75 mg or 100 mg Po QD
- Where
- 3 sites in China
- Volunteers
- 172 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Advanced or Metastatic Solid Tumors
Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
This is a first-in-human, open-label, multicenter, Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of IPH4502 and to determine the recommended Phase 2 dose (RP2D) in advanced solid tumors that are…
- Trial name
- NCT06781983
- Testing
- IPH4502
- Where
- 7 sites in United States, France
- Volunteers
- 145 people
- Sponsor
- Innate Pharma
HER2-positive Breast Cancer, HER2 Gene Mutation
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies.
- Conditions
- HER2-positive Breast Cancer, HER2 Gene Mutation, HER-2 Gene Amplification, HER2 Positive Gastric Cancer
- Trial name
- NCT03602079
- Testing
- A166
- Where
- 10 sites in United States
- Volunteers
- 49 people
- Sponsor
- Klus Pharma Inc.
Non-Small Cell Lung Cancer
Exploratory Study of QBKPN SSI in Non-Small Cell Lung Cancer
The purpose of this study is to evaluate the safety, tolerability, compliance and mechanism of action of study drug (QBKPN SSI) in subjects with two or more second primary pre-invasive or invasive adenocarcinoma following…
- Trial name
- NCT02256852
- Testing
- QBKPN SSI
- Where
- Canada
- Volunteers
- 6 people
- Sponsor
- Qu Biologics Inc.
Small Cell Lung Cancer, Neuroendocrine Cancer
Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer
This is a multicenter, open-label Phase I/II study consisting of two parts: Part 1 is a Phase I dose-escalation study of ZG006, aimed at evaluating the safety and tolerability of ZG006 in Participants with advanced small-cell…
- Trial name
- NCT06283719
- Testing
- ZG006
- Where
- China
- Volunteers
- 265 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Lung Cancer (NSCLC), Prostate Cancer
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
The goal of this clinical trial is to evaluate whether TJ101, an investigational antibody-drug conjugate (ADC), can safely and effectively treat patients with advanced solid tumors.
- Conditions
- Lung Cancer (NSCLC), Prostate Cancer, Esophageal Cancer, Solid Tumor Malignancies
- Trial name
- NCT07181473
- Testing
- TJ101
- Where
- 7 sites in United States, China
- Volunteers
- 200 people
- Sponsor
- Phrontline Biopharma
Carcinoma, Non-Small-Cell Lung, Melanoma
Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.
This is a phase I/Ib, open label study. The escalation portion will characterize the safety and tolerability of DKY709 and DKY709 in combination with PDR001 in subjects with NSCLC or melanoma who have received prior…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Melanoma, Nasopharyngeal Carcinoma, Microsatellite Stable Colorectal Cancer
- Trial name
- NCT03891953
- Testing
- DKY709, PDR001
- Where
- 9 sites in United States, Germany and 4 more
- Volunteers
- 98 people
- Sponsor
- Novartis Pharmaceuticals
Non-small Cell Lung Cancer
An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer
This study was designed to determine the safety and tolerability of PB101 (autologous NK cell product) in combination with standard of care EGFR-TKI in patients with EGFR-mutated advanced non-small cell lung cancer.
- Trial name
- NCT07271446
- Testing
- PB101 plus EGFR-TKI including gefitinib, erlotinib, afatinib, or osimertinib
- Where
- Taiwan
- Volunteers
- 8 people
- Sponsor
- Precision Biotech Taiwan Corp.
Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell
A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors
To characterize safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of QEQ278 in adult patients with advanced/metastatic non-small cell lung cancer, esophageal squamous cell carcinoma…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Esophageal Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT05462873
- Testing
- QEQ278
- Where
- 12 sites in United States, Belgium and 7 more
- Volunteers
- 30 people
- Sponsor
- Novartis Pharmaceuticals
Non-Small Cell Lung Cancer
A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery
To assess the efficacy and safety of sunvozertinib versus placebo as adjuvant therapy in patients with stage IB-IIIA non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations…
- Trial name
- NCT07182682
- Testing
- sunvozertinib
- Where
- 49 sites in China
- Volunteers
- 360 people
- Sponsor
- Dizal (Jiangsu) Pharmaceutical Co., Ltd.
Non-small Cell Lung Cancer
Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKI
The NSCLC patients who experienced good clinical responses to an EGFR-TKI will inevitably develop acquired resistance. A great deal of research are focusing on this issue.
- Trial name
- NCT02066870
- Testing
- Icotinib, Arsenic trioxide
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Solid Tumor Malignancies, Malignant Mesothelioma (MM)
Study of TYK-01054 Capsules in Patients With Advanced Solid Tumors
This study is to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of the TEAD inhibitor TYK-01054 capsules in patients with locally advanced or metastatic advanced solid tumors
- Trial name
- NCT07282873
- Testing
- TYK-01054
- Where
- China
- Volunteers
- 219 people
- Sponsor
- TYK Medicines, Inc
Endometrial Cancer, Squamous Non-Small Cell Lung Cancer
A Study to Assess the Efficacy and Safety of ABTL0812
A phase I/ II, open label study to assess the efficacy and safety of ABTL0812 in combination with paclitaxel and carboplatin in patients with advanced endometrial cancer or squamous NSCLC.
- Trial name
- Endolung (NCT03366480)
- Testing
- ABTL0812 in combination with paclitaxel and carboplatin
- Where
- Spain
- Volunteers
- 103 people
- Sponsor
- Ability Pharmaceuticals SL
Neoplasms, Neoplasm Metastasis
A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors
First-in-human, Phase I/II, Multicenter, Open-Label Study of EMB-01 in Patients with Advanced/Metastatic Solid Tumors
- Conditions
- Neoplasms, Neoplasm Metastasis, Non-Small-Cell Lung Cancer
- Trial name
- NCT03797391
- Testing
- EMB-01
- Where
- 5 sites in United States, China
- Volunteers
- 186 people
- Sponsor
- Shanghai EpimAb Biotherapeutics Co., Ltd.
Small Cell Lung Cancer
Safety Study Using Weekly Infusions of BB-10901 in Patients With Small Cell Lung Cancer
This study was a Phase I/II trial primarily focused on efficacy of BB-10901 in relapsed small cell lung cancer and other solid tumors.
- Trial name
- NCT00065429
- Testing
- BB-10901
- Where
- 11 sites in United States
- Volunteers
- 64 people
- Sponsor
- ImmunoGen, Inc.
Progressive Metastatic Malignancies
Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies
This is a Phase 1, open-labeled, non-randomized, multi-center, competitive enrollment and dose-escalation study of ALT-801, the study drug.
- Trial name
- NCT00496860
- Testing
- ALT-801
- Where
- 4 sites in United States
- Volunteers
- 26 people
- Sponsor
- Altor BioScience